Strategic partnerships Position Haystack MRD as a key collaborator for oncology researchers and biopharma, highlighting ongoing collaborations with Rutgers Cancer Institute and past partnerships to accelerate MRD-driven therapeutic decisions in clinical development.

Clinical adoption Leverage Haystack MRD’s tumor-informed ctDNA approach and 20+ years of oncology genomics heritage to target hospitals and cancer centers pursuing precision MRD monitoring, especially in partnerships with academic and community oncology groups showcased at major conferences.

Clinical trial enablement Target sponsors and CROs running MRD-enabled trials by offering validated, high-sensitivity ctDNA testing to monitor minimal residual disease and treatment response, supported by demonstrated collaborations with research institutions.

Revenue expansion Highlight recurring revenue potential through lab services, companion diagnostics readings, and longitudinal MRD monitoring programs as trials scale, complemented by Quest Diagnostics’ broader laboratory capabilities.

Industry visibility Capitalize on frequent conference participation and active industry presence to drive referrals and inbound interest from oncology specialists, consortiums, and patient-care networks seeking advanced MRD solutions.